Most Active Biotech Investors in London 2026

10 firms writing Biotech checks in London, led by Sofinnova Partners, Life Extension Ventures, Collaborative Fund — ranked by verified deal count.

Biotech in London accounts for 16 tracked companies with verified cap-table data, 16 of which disclose round sizes totalling $1.8B. The median disclosed raise is $100M, and the largest is Verdiva Bio at $411M, ahead of IMU Biosciences ($166M) and Ottimo Pharma ($140M).

The names that recur most often on these biotech cap tables are Forbion (3 companies), Sofinnova Partners (3 companies), Brandon Capital (2 companies), British Patient Capital (2 companies), 8VC (2 companies), General Atlantic (1 company). By latest disclosed round, the market skews Series A (9), Series B (4), IPO (1), Seed (1).

Best funded Biotech in London companies

  1. Verdiva Bio — $411M (latest: Series A)
  2. IMU Biosciences — $166M (latest: Series A)
  3. Ottimo Pharma — $140M (latest: Series A)
  4. Mereo Biopharma — $119M (latest: IPO)
  5. Myricx Bio — $114M (latest: Series A)
  6. Purespring Therapeutics — $105M (latest: Series B)
  7. CoMind — $103M (latest: Series A)
  8. Amber Therapeutics — $100M (latest: Series A)
  9. Basecamp Research — $85M (latest: Series B)
  10. Relation Therapeutics — $80M (latest: Seed)
  11. Beckley Psytech — $80M (latest: Series B)
  12. LabGenius — $75M (latest: Series A)
  13. Pheon Therapeutics — $68M (latest: Series A)
  14. Epsilogen — $60M (latest: Series B)
  15. Automata — $57M (latest: Series C)

Sector × city funding reports (20)

All research · Investor directory · Company funding database · Fundraising library